Panbela Therapeutics, Inc. financial data

Symbol
PBLA on OTC
Industry
Pharmaceutical Preparations
Location
712 Vista Blvd #305, Waconia, MN
State of incorporation
DE
Fiscal year end
December 31
Former names
Sun BioPharma, Inc. (to 12/2/2020), Cimarron Medical, Inc. (to 9/4/2015), CIMARRON SOFTWARE INC (to 5/26/2015)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 15.5 % -74.9%
Debt-to-equity -302 % +50.4%
Return On Equity 546 % -38.9%
Return On Assets -270 % -54%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.85M shares +64.1%
Common Stock, Shares, Outstanding 4.85M shares +85.9%
Entity Public Float 6M USD -47.5%
Common Stock, Value, Issued 5K USD +66.7%
Weighted Average Number of Shares Outstanding, Basic 4.85M shares +13147%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 25.4M USD +87.3%
General and Administrative Expense 4.35M USD -27.4%
Operating Income (Loss) -29.7M USD -52.2%
Nonoperating Income (Expense) 986K USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -28.8M USD -41.6%
Income Tax Expense (Benefit) -177K USD +18.1%
Net Income (Loss) Attributable to Parent -28.6M USD -42.2%
Earnings Per Share, Basic -1.47 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 59K USD -99.2%
Assets, Current 772K USD -92.9%
Other Assets, Noncurrent 8.64M USD -1.14%
Assets 9.41M USD -51.8%
Accounts Payable, Current 14.3M USD +69.3%
Accrued Liabilities, Current 1.41M USD +39.7%
Liabilities, Current 16.8M USD +59.1%
Liabilities 20M USD +35.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 962K USD -2.83%
Retained Earnings (Accumulated Deficit) -140M USD -37%
Stockholders' Equity Attributable to Parent -10.6M USD -320%
Liabilities and Equity 9.41M USD -51.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.39M USD +3.68%
Net Cash Provided by (Used in) Financing Activities 7.08M USD -48.3%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 4.85M shares +85.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.32M USD -159%
Interest Paid, Excluding Capitalized Interest, Operating Activities 266K USD -31.1%
Deferred Tax Assets, Valuation Allowance 26.3M USD +20.6%
Deferred Tax Assets, Gross 26.3M USD +20.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -28.6M USD -44.9%
Deferred Tax Assets, Operating Loss Carryforwards 18.5M USD +5.26%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 128M USD +21.1%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 103K USD -42.8%
Interest Expense 278K USD -28.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%